Braco-19
Based on 5 publication(s) in Google Scholar
Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.01%
- CAS No.: 351351-75-2
- Formula: C35H43N7O2
- Molecular Weight:593.76
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Braco-19
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
IC50: telomerase/telomere[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | EC50 |
113 nM
Compound: 1a
|
Inhibition of telomerase activity from human A2780 cells
Inhibition of telomerase activity from human A2780 cells
|
[PMID: 16420044] |
| A2780 | IC50 |
0.1 μM
Compound: 1
|
Inhibition of telomerase in human A2780 cells by TRAP assay
Inhibition of telomerase in human A2780 cells by TRAP assay
|
[PMID: 19726112] |
| A2780 | IC50 |
10 μM
Compound: 7
|
Cytotoxicity against ovarian carcinoma A2780 cell lines
Cytotoxicity against ovarian carcinoma A2780 cell lines
|
[PMID: 14521409] |
| A-431 | IC50 |
15.8 μM
Compound: 7
|
Cytotoxicity against ovarian carcinoma A431 cell lines
Cytotoxicity against ovarian carcinoma A431 cell lines
|
[PMID: 14521409] |
| A549 | IC50 |
0.09 μM
Compound: BRACO-19
|
Inhibition of human telomerase in A549 cells by TRAP assay
Inhibition of human telomerase in A549 cells by TRAP assay
|
[PMID: 19467742] |
| A549 | IC50 |
2.4 μM
Compound: BRACO-19
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 19053833] |
| A549 | IC50 |
2.42 μM
Compound: 1
|
Growth inhibition of human A549 cells by SRB assay
Growth inhibition of human A549 cells by SRB assay
|
[PMID: 17276687] |
| DU-145 | IC50 |
2.3 μM
Compound: 1
|
Growth inhibition of human DU145 cells by SRB assay
Growth inhibition of human DU145 cells by SRB assay
|
[PMID: 17276687] |
| GIST882 | IC50 |
>25 μM
Compound: BRACO-19
|
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
|
[PMID: 19469547] |
| HEK-293T | IC50 |
45 nM
Compound: BRACO-19
|
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
|
[PMID: 17954919] |
| HEK-293T | IC50 |
65 nM
Compound: BRACO-19
|
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
|
[PMID: 17954919] |
| HEK-293T | IC50 |
830 nM
Compound: BRACO-19
|
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
|
[PMID: 17954919] |
| HeLa | IC50 |
5.25 μM
Compound: BRACO19
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34124673] |
| HGC-27 | IC50 |
2.3 μM
Compound: BRACO-19
|
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
|
[PMID: 29724653] |
| HGC-27 | IC50 |
2.6 μM
Compound: BRACO-19
|
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
|
[PMID: 19469547] |
| HT-29 | IC50 |
2.7 μM
Compound: BRACO-19
|
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 19469547] |
| HT-29 | IC50 |
2.7 μM
Compound: BRACO-19
|
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 29724653] |
| IMR-90 | IC50 |
>25 μM
Compound: 1a
|
Cytotoxicity in human IMR90 cells by SRB assay
Cytotoxicity in human IMR90 cells by SRB assay
|
[PMID: 16420044] |
| MCF7 | IC50 |
2.2 μM
Compound: BRACO-19
|
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 19469547] |
| MCF7 | IC50 |
2.2 μM
Compound: BRACO-19
|
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 29724653] |
| MCF7 | IC50 |
2.5 μM
Compound: BRACO-19
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 19053833] |
| MCF7 | IC50 |
2.53 μM
Compound: 1
|
Growth inhibition of human MCF7 cells by SRB assay
Growth inhibition of human MCF7 cells by SRB assay
|
[PMID: 17276687] |
| MRC5 | IC50 |
8.3 μM
Compound: Braco-19
|
Cytotoxicity against human MRC5 cells
Cytotoxicity against human MRC5 cells
|
[PMID: 38971047] |
| MRC5 | IC50 |
8.33 μM
Compound: BRACO-19
|
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 29323491] |
| U2OS | IC50 |
>40 μM
Compound: BRACO19
|
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
|
[PMID: 31759730] |
| WI-38 | IC50 |
10.7 μM
Compound: BRACO-19
|
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
|
[PMID: 19053833] |
Braco-19, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication[2].BRACO-19 (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC100 is 5 μM[1].BRACO-19 (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses[1].BRACO-19 (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells[2].BRACO-19 (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK 293 cells
-
Concentration:20 μM; 40 μM
-
Incubation Time:24 hours
-
Result:Displayed low cytotoxicity and decreased the eGFP fluorescence.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Established UXF1138LX Xenografts in nude mice[1]
-
Dosage:2 mg/kg
-
Administration:Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments
-
Result:Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.
Chemical Information
-
CAS No. 351351-75-2
-
Appearance Solid
-
Molecular Weight 593.76
-
Formula C35H43N7O2
-
Color Brown to orange
-
SMILES
CN(C1=CC=C(NC2=C(C=CC(NC(CCN3CCCC3)=O)=C4)C4=NC5=CC(NC(CCN6CCCC6)=O)=CC=C52)C=C1)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
Targeting specific DNA G-quadruplexes with CRISPR-guided G-quadruplex-binding proteins and ligands. [Abstract]2024 Jul;26(7):1212-1224. PMID: 38961283 -
Biochim Biophys Acta Mol Basis Dis
The sonic hedgehog pathway suppresses oxidative stress and senescence in nucleus pulposus cells to alleviate intervertebral disc degeneration via GPX4. [Abstract]2023 Nov 16;1870(2):166961. PMID: 37979732 -
iScience
Genomic G-quadruplex folding triggers a cytokine-mediated inflammatory feedback loop to aggravate inflammatory diseases. [Abstract]2022 Oct 9;25(11):105312. PMID: 36304116 -
Microbiol Spectr
Characterization of G-Quadruplexes in Enterovirus A71 Genome and Their Interaction with G-Quadruplex Ligands. [Abstract]2022 Apr 21;e0046022. PMID: 35446122 -
SLAS Discov
A high-throughput approach to evaluating NCp7 RNA binding activity for HIV-1 drug discovery. [Abstract]2025 Aug 11:35:100260. PMID: 40803428
Solvent & Solubility
DMSO : 33.33 mg/mL (56.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.21 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.21 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Angelika M Burger, et al. The G-quadruplex-interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent With Telomere Targeting and Interference With Telomerase Function. Cancer Res. 2005 Feb 15;65(4):1489-96. [Content Brief]
[2]. Prativa Majee, et al. Genome-wide Analysis Reveals a Regulatory Role for G-quadruplexes During Adenovirus Multiplication. Virus Res. . 2020 Jul [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6842 mL | 8.4209 mL | 16.8418 mL | 42.1046 mL |
| 5 mM | 0.3368 mL | 1.6842 mL | 3.3684 mL | 8.4209 mL | |
| 10 mM | 0.1684 mL | 0.8421 mL | 1.6842 mL | 4.2105 mL | |
| 15 mM | 0.1123 mL | 0.5614 mL | 1.1228 mL | 2.8070 mL | |
| 20 mM | 0.0842 mL | 0.4210 mL | 0.8421 mL | 2.1052 mL | |
| 25 mM | 0.0674 mL | 0.3368 mL | 0.6737 mL | 1.6842 mL | |
| 30 mM | 0.0561 mL | 0.2807 mL | 0.5614 mL | 1.4035 mL | |
| 40 mM | 0.0421 mL | 0.2105 mL | 0.4210 mL | 1.0526 mL | |
| 50 mM | 0.0337 mL | 0.1684 mL | 0.3368 mL | 0.8421 mL |
Powered by Bioz